AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities research analysts at Shore Capital in a research note issued to investors on Thursday.
A number of other equities analysts have also commented on the stock. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research report on Tuesday, January 1st. JPMorgan Chase & Co. set a GBX 6,900 ($90.16) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, January 1st. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Monday, January 21st. Societe Generale lifted their price objective on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the company a “buy” rating in a report on Wednesday, January 16th. Finally, HSBC set a GBX 4,860 ($63.50) price objective on shares of AstraZeneca and gave the company a “sell” rating in a report on Wednesday, November 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of GBX 6,243.45 ($81.58).
Shares of LON:AZN opened at GBX 6,012 ($78.56) on Thursday. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: How to execute a trade ex-dividend strategy?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.